Tenon Medical (TNON) Registration filing summary

Company overview and business model

• Focuses on minimally invasive medical devices for sacroiliac (SI) joint disorders, targeting chronic lower back pain patients.

• Offers Catamaran and SImmetry SI Joint Fusion Systems, both FDA-cleared, with differentiated surgical approaches.

• Acquired assets from SiVantage, Inc. and SIMPL Medical, LLC in August 2025 to expand product portfolio.

• Commercial strategy includes primary SI joint procedures, revision surgeries, and adjuncts to spine fusion.

• Operates primarily in the US, with ongoing clinical studies and physician training initiatives.

Financial performance and metrics

• As of March 31, 2026, net tangible book value was approximately $(982,000), or $(0.087) per share.

• After the offering, pro forma net tangible book value would be $0.114 per share, with immediate dilution of $0.488 per share to new investors.

• Stockholders' equity reported at $1,895,000 as of March 31, 2026, below Nasdaq's minimum requirement.

• Substantial doubt expressed by auditors regarding ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds estimated at $2,972,500 if fully subscribed, after fees and expenses.

• Planned uses: partial repayment of convertible notes, expansion of commercial footprint, clinician training, hiring sales reps, expanding distribution, clinical research, R&D for future launches, inventory and instrumentation increases, marketing, and working capital.

• Management retains broad discretion over allocation of proceeds.